PFEHealthcare · Drug Manufacturers - GeneralThe 28 Wall Street analysts covering Pfizer Inc. hold a median 12-month price target of $29 — -3.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 14 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Pfizer Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (98): The share price has been relatively steady.
Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PFE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −3.1% from it.
Of the 20 most recent actions, 4 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | JP Morgan | Maintains | Neutral | $28 → $30 |
| 8 Oct 2026 | Cantor Fitzgerald | Maintains | Neutral | $27 → $28 |
| 6 Oct 2026 | Scotiabank | Maintains | Sector Outperform | $30 → $33 |
| 10 Sept 2026 | HSBC | Maintains | Hold | $28 → $30 |
| 10 Sept 2026 | HSBC | Maintains | Hold | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $35 → $31 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 13 July 2026 | BMO Capital | Maintains | Outperform | $34 → $30 |
| 13 July 2026 | BMO Capital | Maintains | Outperform | — |
| 13 July 2026 | Guggenheim | Maintains | Buy | — |
| 13 July 2026 | Guggenheim | Maintains | Buy | $36 → $35 |
| 10 July 2026 | B of A Securities | Maintains | Neutral | $27 → $26 |
| 10 July 2026 | B of A Securities | Maintains | Neutral | — |
| 8 July 2026 | JP Morgan | Maintains | Neutral | $30 → $28 |
| 8 July 2026 | JP Morgan | Maintains | Neutral | — |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | $27 |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 6 July 2026 | HSBC | Downgrade | Hold | — |
| 6 July 2026 | HSBC | Downgrade | Hold | $32 → $28 |
| 10 June 2026 | RBC Capital | Upgrade | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PFE appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Pfizer Inc. returned +28.9% against +16.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 20% of US stocks
Cheaper than 45% of US stocks
Cheaper than 45% of US stocks
Cheaper than 43% of US stocks
Higher than 33% of US stocks
Higher than 39% of US stocks
Higher than 85% of US stocks
Higher than 86% of US stocks
Higher than 64% of US stocks
Higher than 54% of US stocks
Higher than 80% of US stocks
Higher than 94% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pfizer Inc. has a market value of $161.7B and an enterprise value of $213.9B.
Revenue in the twelve months to 30 June 2026: $63.7B. The latest quarter grew 2.6% year on year.
Net income over the same four quarters: $4.4B, a 6.9% net margin.
Diluted earnings per share, trailing twelve months: $0.76.
Free cash flow in the twelve months to 30 June 2026: $11.0B.
Pfizer Inc. spent $9.8B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 37.3×; forward P/E: 9.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 6.06%, paying out 226% of earnings.
Pfizer Inc. employs 75,000 people — $849K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pfizer Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Healthcare stocks attracted buying as investors rotated away from technology. Moderna rose 6%, while BioNTech and Pfizer edged higher.
Why it matters — The report notes modest gains in Pfizer shares amid increased investor interest in healthcare.
The Motley Fool compares AbbVie and Pfizer as healthcare stocks for 2026, noting that AbbVie’s newer drugs are growing quickly enough to more than replace Humira revenue. It says the hardest part of AbbVie’s transition appears to be behind it.
Why it matters — The comparison offers context for PFE watchers by highlighting AbbVie’s progress replacing revenue from Humira.
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss of Short Hills Capital Partners picked the U.S. 10 Year Treasury.
Why it matters — The excerpt mentions no Pfizer-specific development; it only reports a Treasury pick in a segment whose headline also names Pfizer.
Pfizer shares settled at $29.21 on the latest trading day, up 2.96% from the previous close, while the broader market dipped.
Why it matters — The item reports a daily gain in PFE despite a decline in the market.
Pfizer's non-COVID revenue grew 18% year over year, and its oncology pipeline is deepening, including through a new partnership.
Why it matters — The revenue growth and oncology developments highlight areas that could broaden Pfizer's business and support future growth.
The 28 Wall Street analysts covering Pfizer Inc. have a median 12-month price target of $29, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Pfizer Inc., 10 rate it a Buy, 16 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Pfizer Inc. 84 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Pfizer Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies -3.1% from the last close, and Ticker Nerd's factor model ranks Pfizer Inc. 84 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pfizer Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.
Pfizer Inc. returned +28.9% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide.
The most recent item we track (24/7 Wall Street, 15 Oct 2026): "Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher". Healthcare stocks attracted buying as investors rotated away from technology. Moderna rose 6%, while BioNTech and Pfizer edged higher.
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems. Pfizer also maintains a consumer health presence through established over-the-counter and wellness products in select markets. The company plays a central role in global healthcare by supplying prescription therapies and immunizations across major therapeutic areas, while its research and development organization continues to support the launch, approval, and lifecycle management of new treatments. Founded in 1849 and headquartered in New York City, Pfizer Inc. remains one of the most recognized names in the pharmaceutical industry.
CEO Dr. Albert Bourla D.V.M., Ph.D. · 75,000 employees · United States · https://www.pfizer.com
